What is HC Wainwright's Estimate for MindWalk Q2 Earnings?

Key Points

• HC Wainwright lowered its Q2 2027 EPS estimate for MindWalk to a loss of $0.05 per share, from a previous estimate of $0.04, while maintaining a “Buy” rating.
• HC Wainwright forecasts losses of $0.07 per share in Q3 2027, $0.08 in Q4, and $0.28 for both FY2027 and FY2028.
• MindWalk’s latest quarter fell short of expectations, reporting a $0.09 per-share loss versus the $0.05 consensus estimate and revenue of $2.73 million versus $3.25 million expected.

MindWalk Holdings Corp. (NASDAQ:HYFT - Free Report) - Analysts at HC Wainwright decreased their Q2 2027 earnings per share (EPS) estimates for MindWalk in a report issued on Wednesday, September 23rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.05) per share for the quarter, down from their previous estimate of ($0.04). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for MindWalk's current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for MindWalk's Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.28) EPS and FY2028 earnings at ($0.28) EPS.

MindWalk (NASDAQ:HYFT - Get Free Report) last announced its quarterly earnings data on Monday, September 14th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.04). MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%.The business had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.25 million.

HYFT has been the topic of a number of other reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of MindWalk in a research report on Wednesday, July 15th. Wall Street Zen upgraded shares of MindWalk from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Finally, Zacks Research upgraded shares of MindWalk from a "strong sell" rating to a "hold" rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, MindWalk currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.00.

MindWalk Price Performance

Shares of HYFT opened at $1.36 on Friday. The business's 50-day moving average is $1.35 and its 200-day moving average is $1.37. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.84 and a quick ratio of 1.75. The company has a market capitalization of $63.53 million, a price-to-earnings ratio of -5.23 and a beta of 0.82. MindWalk has a fifty-two week low of $0.99 and a fifty-two week high of $2.99.

Hedge Funds Weigh In On MindWalk

An institutional investor recently bought a new stake in MindWalk stock. GSA Capital Partners LLP acquired a new stake in shares of MindWalk Holdings Corp. (NASDAQ:HYFT - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 34,525 shares of the company's stock, valued at approximately $55,000. GSA Capital Partners LLP owned about 0.07% of MindWalk as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.70% of the company's stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.